S V Hope1,2, B A Knight1, B M Shields1, A T Hattersley1,3, T J McDonald1,4, A G Jones5,6. 1. NIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK. 2. Department of Geriatrics, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK. 3. Department of Diabetes & Endocrinology, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK. 4. Department of Blood Sciences, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK. 5. NIHR Exeter Clinical Research Facility, University of Exeter Medical School, Exeter, UK. Angus.Jones@exeter.ac.uk. 6. Department of Diabetes & Endocrinology, Royal Devon & Exeter NHS Foundation Trust, Exeter, UK. Angus.Jones@exeter.ac.uk.
Abstract
BACKGROUND: Measuring endogenous insulin secretion using C-peptide can assist diabetes management, but standard stimulation tests are impractical for clinical use. Random non-fasting C-peptide assessment would allow testing when a patient is seen in clinic. METHODS: We compared C-peptide at 90 min in the mixed meal tolerance test (sCP) with random non-fasting blood C-peptide (rCP) and random non-fasting urine C-peptide creatinine ratio (rUCPCR) in 41 participants with insulin-treated diabetes [median age 72 (interquartile range 68-78); diabetes duration 21 (14-31) years]. We assessed sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency (sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of concurrent glucose. RESULTS: rCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP, r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut-off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l. rUCPCR (0.52 nmol/mmol) was also well-correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut-off of < 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area under the receiver operating characteristic curve of 0.98. CONCLUSIONS: Random non-fasting C-peptide measures are strongly correlated with mixed meal C-peptide, and have high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C-peptide at the point patients are seen for clinical care.
BACKGROUND: Measuring endogenous insulin secretion using C-peptide can assist diabetes management, but standard stimulation tests are impractical for clinical use. Random non-fasting C-peptide assessment would allow testing when a patient is seen in clinic. METHODS: We compared C-peptide at 90 min in the mixed meal tolerance test (sCP) with random non-fasting blood C-peptide (rCP) and random non-fasting urine C-peptide creatinine ratio (rUCPCR) in 41 participants with insulin-treated diabetes [median age 72 (interquartile range 68-78); diabetes duration 21 (14-31) years]. We assessed sensitivity and specificity for previously reported optimal mixed meal test thresholds for severe insulin deficiency (sCP < 200 pmol//l) and Type 1 diabetes/inability to withdraw insulin (< 600 pmol//l), and assessed the impact of concurrent glucose. RESULTS: rCP and sCP levels were similar (median 546 and 487 pmol//l, P = 0.92). rCP was highly correlated with sCP, r = 0.91, P < 0.0001, improving to r = 0.96 when excluding samples with concurrent glucose < 8 mmol//l. An rCP cut-off of 200 pmol//l gave 100% sensitivity and 93% specificity for detecting severe insulin deficiency, with area under the receiver operating characteristic curve of 0.99. rCP < 600 pmol//l gave 87% sensitivity and 83% specificity to detect sCP < 600 pmol//l. Specificity improved to 100% when excluding samples with concurrent glucose < 8 mmol//l. rUCPCR (0.52 nmol/mmol) was also well-correlated with sCP, r = 0.82, P < 0.0001. A rUCPCR cut-off of < 0.2 nmol/ mmol gave sensitivity and specificity of 83% and 93% to detect severe insulin deficiency, with area under the receiver operating characteristic curve of 0.98. CONCLUSIONS: Random non-fasting C-peptide measures are strongly correlated with mixed meal C-peptide, and have high sensitivity and specificity for identifying clinically relevant thresholds. These tests allow assessment of C-peptide at the point patients are seen for clinical care.
Authors: Tim J McDonald; Bridget A Knight; Beverley M Shields; Pamela Bowman; Maurice B Salzmann; Andrew T Hattersley Journal: Clin Chem Date: 2009-08-27 Impact factor: 8.327
Authors: A G Jones; R E J Besser; T J McDonald; B M Shields; S V Hope; P Bowman; R A Oram; B A Knight; A T Hattersley Journal: Diabet Med Date: 2011-09 Impact factor: 4.359
Authors: Rachel E J Besser; Johnny Ludvigsson; Angus G Jones; Timothy J McDonald; Beverley M Shields; Bridget A Knight; Andrew T Hattersley Journal: Diabetes Care Date: 2011-02-01 Impact factor: 19.112
Authors: Gaya Thanabalasingham; Aparna Pal; Mary P Selwood; Christina Dudley; Karen Fisher; Polly J Bingley; Sian Ellard; Andrew J Farmer; Mark I McCarthy; Katharine R Owen Journal: Diabetes Care Date: 2012-03-19 Impact factor: 19.112
Authors: Carla J Greenbaum; Thomas Mandrup-Poulsen; Paula Friedenberg McGee; Tadej Battelino; Burkhard Haastert; Johnny Ludvigsson; Paolo Pozzilli; John M Lachin; Hubert Kolb Journal: Diabetes Care Date: 2008-07-15 Impact factor: 19.112
Authors: Timothy J McDonald; Mandy H Perry; Roy W A Peake; Nicola J Pullan; John O'Connor; Beverley M Shields; Beatrice A Knight; Andrew T Hattersley Journal: PLoS One Date: 2012-07-30 Impact factor: 3.240
Authors: Rachel E J Besser; Beverley M Shields; Rosaura Casas; Andrew T Hattersley; Johnny Ludvigsson Journal: Diabetes Care Date: 2012-10-30 Impact factor: 19.112
Authors: David T Broome; Kevin M Pantalone; Sangeeta R Kashyap; Louis H Philipson Journal: J Clin Endocrinol Metab Date: 2021-01-01 Impact factor: 5.958
Authors: Beverley M Shields; Timothy J McDonald; Richard Oram; Anita Hill; Michelle Hudson; Pia Leete; Ewan R Pearson; Sarah J Richardson; Noel G Morgan; Andrew T Hattersley Journal: Diabetes Care Date: 2018-06-07 Impact factor: 19.112
Authors: Ana Sorina Dănescu; Ioana Bâldea; Daniel Corneliu Leucuţa; Iulia Lupan; Gabriel Samaşca; Cassian Sitaru; Roxana Chiorean; Adrian Baican Journal: Medicine (Baltimore) Date: 2018-04 Impact factor: 1.889
Authors: Nicholas J Thomas; Anita L Lynam; Anita V Hill; Michael N Weedon; Beverley M Shields; Richard A Oram; Timothy J McDonald; Andrew T Hattersley; Angus G Jones Journal: Diabetologia Date: 2019-04-10 Impact factor: 10.122
Authors: Suzy V Hope; Bridget A Knight; Beverley M Shields; Anita V Hill; Pratik Choudhary; W David Strain; Timothy J McDonald; Angus G Jones Journal: Diabetologia Date: 2017-10-05 Impact factor: 10.122